Search results
Press Releases: Advanced Cell Technology, Inc. Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries. 16-02-10. PR.
- News
All the latest stock market and economic news. Follow live...
- Company Profile
Company details: Advanced Cell Technology, Inc. Astellas...
- Calendar
Calendar Advanced Cell Technology, Inc. OTC Bulletin Board...
- News
Jan 8, 2013 · Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC or the "Company"), a leader in the field of regenerative medicine, announced today that investigators for the Company's Phase I/II clinical trials for Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) have observed evidence of engraftment of the transplanted ...
Aug 26, 2014 · 236 Follower s. Follow. Summary. Uplisting must allow post-publication share price to run and range, before a reverse split. A reverse split can affect short- and long-term profits. It doesn't...
Proterra serves customers worldwide. Company profile page for Proterra Inc including stock price, company news, executives, board members, and contact information.
- 1.2K
Feb 15, 2002 · Company details: Advanced Cell Technology, Inc. Astellas Institute for Regenerative Medicine. 33 Locke Drive. 01752, Marlborough. +508-756-1212. https://www.ocata.com.
Jan 1, 2011 · Advanced Cell Technology (OTCBB:ACTC) confirmed this morning that it had lined up a US$25 million non-convertible stock purchase agreement with a subsidiary of Socius Capital Group of Los Angeles - a life sciences investment firm.
Dec 31, 2010 · Under the agreement, ACT may sell up to 2,500 shares of non-convertible Series C Preferred Stock to Socius over a two-year period. On closing, Socius purchased 400 shares of Series C Preferred...
